ferric carboxymaltose - Profile

What are the generic sources for ferric carboxymaltose and what is the scope of freedom to operate?

Ferric carboxymaltose is the generic ingredient in one branded drug marketed by Am Regent and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ferric carboxymaltose has seventy-one patent family members in thirty-two countries.

Summary for ferric carboxymaltose

International Patents:	71
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ferric carboxymaltose

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ferric carboxymaltose

Dosage:

INJECTABLE;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for FERRIC CARBOXYMALTOSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INJECTAFER	Injection	ferric carboxymaltose	500 mg/10 mL	203565	1	2024-02-22
INJECTAFER	Injection	ferric carboxymaltose	100 mg/2 mL	203565	1	2022-09-23
INJECTAFER	Injection	ferric carboxymaltose	1 g/20 mL	203565	1	2022-02-15
INJECTAFER	Injection	ferric carboxymaltose	750 mg/15 mL	203565	1	2019-03-27

US Patents and Regulatory Information for ferric carboxymaltose

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021		RX	Yes	Yes			Y	Y

Expired US Patents for ferric carboxymaltose

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-004	Feb 4, 2022
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-004	Feb 4, 2022
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-002	Oct 8, 2020
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-002	Oct 8, 2020
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-001	Jul 25, 2013
Am Regent	INJECTAFER	ferric carboxymaltose	SOLUTION;INTRAVENOUS	203565-003	Apr 28, 2021

International Patents for ferric carboxymaltose

Country	Patent Number	Title	Estimated Expiration
Jordan	3286	متراكبات مائية من حديد و كربوهيدرات,انتاجها و ادوية تحتوي عليها (AQUEOUS IRON CARBOHYDRATE COMPLEXES,THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM)
South Korea	100992178
Lithuania	1973549
Lithuania	1973549
European Patent Office	1973549	MÉTHODES ET COMPOSITIONS POUR L'ADMINISTRATION DE FER (METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON)
Hong Kong	1149574	WATER-SOLUBLE IRON-CARBOHYDRATE COMPLEXES, PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING SAID COMPLEXES

Supplementary Protection Certificates for ferric carboxymaltose

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1554315	C01554315/01	Switzerland		PRODUCT NAME: EISEN ALS EISENCARBOXYMALTOSE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 57851 10.11.2022

FERRIC CARBOXYMALTOSE: INVESTMENT SCENARIO, MARKET DYNAMICS, AND FINANCIAL TRAJECTORY

Last updated: February 3, 2026

---

Summary

Ferric carboxymaltose (FCM) is an intravenous iron formulation primarily used for iron deficiency anemia treatment. Its fast action, high dosing capacity, and favorable safety profile have expanded its global adoption, positioning it as a key asset in infectious diseases and chronic disease management markets. This analysis examines the current market landscape, growth drivers, competitive positioning, and financial prospects of FCM, based on recent industry reports and patent data. It further projects its trajectory through 2030, emphasizing market expansion, regulatory developments, and competitive dynamics.

---

1. Market Overview for Ferric Carboxymaltose

Parameter	Details
Market Size (2022)	Approximately $2.15 billion globally
CAGR (2022–2030)	Estimated 7.5%
Key Regions	North America, Europe, Asia-Pacific
Major Players	Takeda Pharmaceuticals (Vifor/Fresenius), Pharmacosmos, Teva, China-based companies

Sources indicate Takeda’s Vifor division dominates, holding approximately 50% of the global market share in IV iron therapies [1].

---

2. Market Drivers and Inhibitors

Drivers:

• Rising Prevalence of Iron Deficiency Anemia (IDA): Global increase driven by aging populations, obesity, and chronic diseases.
• Advantages over Oral Iron: Rapid iron replenishment, tolerability, and reduced gastrointestinal side effects.
• Expanding Clinical Applications: Use in heart failure, CKD, postpartum anemia, and specific surgical procedures.
• Regulatory Approvals in Key Markets: FDA, EMA, and other agencies approving FCM for multiple indications.
• Product Innovation and Formulation Advances: Higher single-dose capacity (up to 1,000 mg per infusion), reducing treatment time.

Inhibitors:

• Pricing and Reimbursement Pressures: Particularly in Europe and Asia.
• Entry of Biosimilars and Generics: Patent expiries and pipeline competition.
• Safety Concerns and Rare Adverse Events: Anaphylaxis risk, though low, remains a factor.
• Market Penetration Challenges: Especially in low-resource settings with limited healthcare infrastructure.

---

3. Competitive Landscape

Company	Product Name	Market Share	Key Differentiators	Regulatory Status
Takeda / Vifor	Injectafer (Ferinject)	~50%	Established safety profile, wide approval	Approved in US, EU, Asia
Pharmacosmos	Monofer	~20%	Strong in Europe, cost-effective	Approved in EU, under review in US
Teva	Ferrlecit	Varied by region	Generic competitor	Approved in multiple regions
Others	Various regional brands	Remaining	Local market dominance and pricing	Regulatory-specific

---

4. Financial Trajectory (2023–2030 Projection)

Year	Estimated Market Size (USD Billions)	Growth Rate (CAGR)	Key Factors
2022	2.15	—	Baseline
2023	2.31	7.5%	Increased adoption, new indication approvals
2024	2.49	7.5%	Expansion in Asia-Pacific and emerging markets
2025	2.67	7.5%	Greater hospital and outpatient adoption
2026	2.87	7.4%	Pricing adjustments and reimbursement policies
2027	3.07	7.1%	Patent protections, limited biosimilar impact
2028	3.31	7.4%	Broader indications, global uptake
2029	3.56	7.5%	Aging populations, chronic care expansion
2030	3.83	7.5%	Consolidation in market, innovation pipeline

Note: The projections assume continued favorable market dynamics, with the possibility of acceleration due to unmet needs and niche applications.

---

5. Regulatory and Patent Dynamics

Aspect	Details
Patent Expiry Date	Key patents held by Takeda/Vifor expiring 2027–2028 at major markets
Regulatory Approvals	US FDA (2013), EMA (2014), Japan, China, and emerging markets
Biosimilar Entry Impact	Potential price erosion and market share redistribution post-2027
Orphan and Specialty Disease Designations	Supporting future indications and exclusivities

---

6. SWOT Analysis

Strengths	Weaknesses
Established clinical efficacy	Patent expiries approaching, biosimilar competition
Favorable safety profile	High initial costs for infusion devices
Wide regulatory acceptance	Limited penetration in low-resource regions

Opportunities	Threats
Increasing treatment for anemia in chronic disease	Biosimilar market entrants affecting pricing
Expansion into emerging markets	Safety concerns affecting uptake
Pipeline innovations for broader indications	Healthcare reimbursement policies shifting

---

7. Investment Considerations

• Market Penetration: Growth potential hinges on expanding access, especially in Asia-Pacific and Africa.
• Pipeline Development: New formulations or indications (e.g., intraoperative anemia) could provide valuation uplifts.
• Patent Strategy: Firms must innovate or secure exclusivity to deter biosimilar erosion.
• Pricing and Reimbursement Policies: Evolving policies could alter revenue streams.
• Partnerships and M&A: Strategic alliances might accelerate market share gains amid competition.

---

8. Deep Dive into Competitive Advantages

Takeda (Vifor): Dominant market leader with broad approvals, extensive clinical data, and established distribution channels.

Pharmacosmos: Focused European market penetration with competitive pricing.

Emerging Players: Chinese biotech and generic firms expanding rapidly, especially with local regulatory support.

Competitive Edge	Description
Clinical Evidence	Extensive trials demonstrating efficacy and safety
Regulatory Network	Multiple approvals facilitating global expansion
Pricing Strategy	Tiered pricing, discounts, and volume-based incentives
Innovation Pipeline	Next-generation formulations and broader disease indications

---

9. Frequently Asked Questions (FAQs)

Q1: What are the main drivers for investing in ferric carboxymaltose?
A1: Rising prevalence of anemia, benefits over oral iron therapies, expanding indications, and regulatory support.

Q2: How do patents influence market dynamics?
A2: Patent expiries around 2027–2028 open opportunities for biosimilars, potentially reducing prices and market share for original formulations.

Q3: Which regions present the highest growth opportunities?
A3: Asia-Pacific, Latin America, and parts of Africa due to increasing healthcare infrastructure and unmet needs.

Q4: What are key risks associated with FCM investments?
A4: Biosimilar competition, pricing pressures, safety concerns, and regulatory shifts.

Q5: How does the competitive landscape affect the financial outlook?
A5: Market dominance by large players offers stability, but new entrants and biosimilars may pressure margins and limit growth.

---

10. Key Takeaways

• Market Opportunity: The global IV iron market, led by ferric carboxymaltose, is poised for steady growth (~7.5% CAGR), driven by increasing anemia prevalence and expanding indications.
• Strategic Positioning: Takeda/Vifor maintains a dominant position; success depends on continued innovation, regulatory navigation, and market expansion.
• Competitive Challenges: Patent expiries and biosimilar entries present imminent risks; companies investing in pipeline and partnerships can mitigate impacts.
• Regional Expansion: Emerging markets represent high-growth areas, contingent on healthcare infrastructure development.
• Financial Outlook: Revenues are expected to approach $3.8 billion globally by 2030, provided market access and competitive dynamics remain favorable.

---

References

[1] Global IV Iron Market Report 2022-2030, Market Research Future.
[2] Takeda (Vifor) Annual Reports, 2022.
[3] European Medicines Agency (EMA) Approval Documentation, 2014.
[4] FDA Drug Approvals Database, 2013.
[5] Industry Patent Databases, 2022.

---

Note: All projections and insights are subject to market variations, policy changes, and technological advancements. Continuous monitoring is essential for accurate investment decision-making.